Cheaper cancer care therapy earns big bucks for pharma company
ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore.
Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018.
ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India.
In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are exhausted.Each CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks up.Meanwhile, ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic advisor.Rahul Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion."
Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
16 minutes ago
- Time of India
Italy's opposition warns against involving SpaceX in satellite update
Academy Empower your mind, elevate your skills Italy's main opposition Democratic Party (PD) has warned Giorgia Meloni's ruling coalition against involving Elon Musk's SpaceX in the update of a satellite programme, parliamentary documents show, saying the move would pose national security risks.A lower house defence committee approved this week a government proposal which includes replacing an old satellite system, named SICRAL, with a new system, first launched in 2001, has been developed by Telespazio and Thales Alenia Space, two joint ventures between Italy's aerospace and defence group Leonardo and France's PD asked the government to make clear that SpaceX would not be called in to help launch the SICRAL 3 satellite into orbit. Defence Undersecretary Isabella Rauti said the administration would assess its options, but SpaceX was the most advanced company available on the market."We only want Italian or European companies to be involved in a security matter such as SICRAL," PD lawmaker and defence committee member Stefano Graziano told Reuters. His party abstained from the opposition parties have repeatedly urged the government to prevent Musk and his companies from becoming involved in national security matters, amid concerns over the influence he wields through his Starlink satellite has been rushing to find viable alternatives to SpaceX's low orbit satellites for communications and intelligence while launching platforms to ensure independent access to space, as pan-European projects still lag a friend of Prime Minister Meloni, held talks with Italian officials over a potential telecommunications contract, but discussions stalled earlier this year amid mounting political controversy."The deployment of the SICRAL 3 satellite addresses the need to strengthen national connectivity and provide Italy with strategic independence in long-range communications," Rauti told did not immediately respond to an emailed request for comment on this SICRAL system uses geostationary satellites for confidential strategic and tactical communications, to support defence missions both in Italy and Italian government will invest a total 767 million euros ($878 million) through 2028 in the programme, the documents show. Rauti said the new satellite would be launched by the first half of 2027.
Time of India
16 minutes ago
- Time of India
With Iveco in its kitty, Tata Motors set to expand global truck footprint
New Delhi: It was a little over two decades ago, 2004 to be precise, when Tata Motors acquired Daewoo Commercial Vehicle Company. This was seen as a big step forward in its endevaour to become a global truck and bus maker. The company has now gone one step further with the recent acquisition of Italy's Iveco Group for €3.8 billion (approx ₹38,240 crore). The deal includes Iveco's truck, bus, and powertrain operations, as well as its financial services arm. 'The Daewoo acquisition helped us understand how to compete with global CV giants, as Daewoo operates in a market alongside players like Daimler, Volvo, and Traton,' Girish Wagh, Executive Director, Tata Motors Ltd, told ETAuto during a media briefing on Thursday. He added that the Korean venture also served as a proving ground for cross-border synergies. 'For instance, all of Daewoo's medium and heavy-duty trucks use a cabin developed in India and jointly adapted for the Korean market. Even our entry into the light-duty segment there was built on Indian-developed aggregates.' 'With that experience, we've built strong capabilities in cross-cultural integration and collaborative product development, and we intend to scale significantly as we begin our journey with Iveco,' Wagh said. Hinting at the significant potential the current deal could unlock for Tata Motors, Group CFO PB Balaji remarked, 'I know many are seeing this as simply putting two and two together, but if two and two only make four, we have a problem.' What excites him more, he added, is the prospect of two and two becoming six, eight, or even twenty-two, if the companies can truly unlock the synergy and scale. Strategic focus The Mumbai-based automaker plans to operate its commercial vehicle business as a unified entity. Iveco's portfolio will be introduced in India, while Tata's products will gain wider access to global markets, supported by integrated sales, service, and distribution networks. The company will also explore platform sharing and convergence in future product development to optimise R&D investments. 'However, drawing from its JLR experience, Tata Motors intends to retain Iveco's brand identity, customer interface, and distribution channels as independent to preserve market-specific strengths,' he said. With this deal, Tata is looking to tap into 'premium customer segments and cohorts' that the company currently does not address. Balaji noted that Iveco's investments in advanced technologies like powertrains, SDVs, and ADAS are ahead of the curve. Its alliances with Ford Otosan for cabin development and Hyundai Motor Company for fuel cells will offer Tata Motors strong tech leverage amid the industry's ongoing transition. Labour integration As part of the acquisition terms, Tata Motors has agreed to a set of non-financial covenants that will remain in force for two years post-deal closure. 'There is no overlap in the industrial footprint, so the strategic rationale itself ensures job security,' Balaji said. 'Iveco will continue to take decisions required to remain competitive under its own 'Unlimited Pathways' framework. The transaction neither accelerates nor impairs that direction. We remain neutral from that standpoint,' he added. In a joint statement, Italy's Chigi Palace and the Council of Ministers welcomed the Tata Motors-Iveco deal, calling it 'a major industrial transaction' that opens new growth avenues for Iveco Group and its workforce. Iveco's legacy Iveco was spun off from the Fiat Group in 2009 as part of Fiat Industrial, later becoming part of CNH Global, and finally emerging as a separately listed entity in 2022. Its key manufacturing hubs are located in Italy, Spain, and Brazil. The company operates across four main business segments, with its truck division being the largest contributor, generating around €10 billion in revenue in CY2024, with an EBIT margin of 5.6 per cent. Iveco holds approximately 11 per cent market share across the European Union and Latin American markets. In the bus segment, the company reported revenues of €2.6 billion last year with an EBIT margin of 5.5 per cent, making it the second-largest bus manufacturer in Europe. It operates across city, intercity, and minibus segments, with production facilities in the Czech Republic and France. The powertrain division, FPT Industrial, posted €3.5 billion in revenue in CY2024 with a 6.2 per cent EBIT margin. FPT is currently the fifth-largest engine manufacturer globally, with most of its production centered in Italy. In powertrains, the Italian company aims to be the 'last man standing' in internal combustion engines (ICEs), while also making significant recent investments in electric drivetrains. Excluding defence, Iveco reported revenues of €14 billion.
Economic Times
16 minutes ago
- Economic Times
Emami shares rally 8% after Q1 profit climbs 9% despite summer slump
Shares of Emami Ltd climbed as much as 8.3% on Thursday to Rs 611.80 on the BSE after the FMCG major reported a 9.3% year-on-year jump in its June-quarter net profit, defying weak summer sales and muted urban demand. ADVERTISEMENT The Kolkata-based company posted a consolidated net profit of Rs 164.26 crore for the three months ended June 2025, up from Rs 150.60 crore a year earlier. The upbeat bottom line came even as revenue from operations edged marginally lower to Rs 904.09 crore from Rs 906.07 crore in the year-ago quarter. "The quarter witnessed persistent pressure on urban discretionary consumption, while rural demand displayed signs of recovery," Emami said in a press statement. "However, an unusually soft and shortened summer, caused by unseasonal rainfall and the early arrival of the monsoon, negatively impacted consumption across the company's summer-centric portfolio."Despite these headwinds, the company managed to deliver a steady operating performance. Total income rose slightly to Rs 925.68 crore, while total expenses remained flat at Rs 689.87 crore. Gross margins expanded by 170 basis points to 69.4%, supported by "benign input costs and judicious price increases." Operating profit (EBITDA) came in at Rs 214 crore. Excluding the seasonal talc and personal hygiene powder (PHP) portfolio, Emami's domestic business clocked a 6% revenue growth for the quarter. ADVERTISEMENT "Revenues remained broadly flat on a year-on-year basis, with a 2-year CAGR of 5%," the company said, adding that "categories like the Pain Management range and BoroPlus Antiseptic Creams delivered strong growth during the quarter."Emami's international operations also posted modest growth, despite "ongoing macroeconomic and geopolitical uncertainties across key markets such as Bangladesh, the Middle East, and Africa." The company said it remained focused on building long-term value in these regions through "focused portfolio strategies and localized innovations." ADVERTISEMENT Profit before tax rose to Rs 186.77 crore, up from Rs 178.38 crore in the same quarter last ahead, Emami expressed confidence that the operating environment would turn more favourable, aided by "a buoyant monsoon, stabilizing inflation, and ongoing consumption recovery." ADVERTISEMENT "With strategic levers of innovation, distribution expansion, digital acceleration, and cost agility firmly in place, the Company is well-positioned to drive sustainable and profitable growth in the quarters ahead," the company said. Thursday's rally lifted Emami shares above all key simple moving averages, from 5-day to 200-day, signalling bullish momentum across timeframes. The Relative Strength Index (RSI) stood at 41.9, indicating neutral territory, while the MACD remained in bearish alignment, with the indicator below both its center line and signal stock has gained 27% over the past 12 months and is up 4.5% in the past month. However, it remains down 4.4% over the last three months. ADVERTISEMENT Also read | CDSL shares slide 13% in one week as NSDL IPO picks pace (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
